APA (7th ed.) Citation

FP, M. R., G, X., GF, K., J, N., R, M., B, S., . . . J, B. (2024). Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer letters, 584, 216608. https://doi.org/10.1016/j.canlet.2024.216608

Chicago Style (17th ed.) Citation

FP, Madorsky Rowdo, et al. "Patient-derived Tumor Organoids with P53 Mutations, and Not Wild-type P53, Are Sensitive to Synergistic Combination PARP Inhibitor Treatment." Cancer Letters 584 (2024): 216608. https://doi.org/10.1016/j.canlet.2024.216608.

MLA (9th ed.) Citation

FP, Madorsky Rowdo, et al. "Patient-derived Tumor Organoids with P53 Mutations, and Not Wild-type P53, Are Sensitive to Synergistic Combination PARP Inhibitor Treatment." Cancer Letters, vol. 584, 2024, p. 216608, https://doi.org/10.1016/j.canlet.2024.216608.